A mesothelioma prognosis prediction method, molecular marker and kit and application thereof

By constructing a multi-factor cox iterative regression model, using the expression signal of ferrodysfunction genes to predict mesothelioma prognosis, the problem of inaccurate prediction of mesothelioma in the prior art was solved, and the prediction effect of high accuracy and sensitivity was achieved.

CN118086505BActive Publication Date: 2024-11-22SUN YAT SEN MEMORIAL HOSPITAL SUN YAT SEN UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410374007.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-03-29
Publication Date
2024-11-22
Estimated Expiration
2044-03-29

AI Technical Summary

Technical Problem

The prior art lacks effective mesothelioma prognosis prediction methods and markers, resulting in inaccurate prognosis prediction, and the application of ferrodynamic genes in mesothelioma has not been fully studied.

Method used

Nine ferrodysfunction regulators with prognostic importance were identified through univariate Cox regression analysis, and a multivariate cox iterative regression model was constructed, and the expression signals of CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4 were used for Mesothelioma prognosis prediction, molecular markers and kits for mesothelioma prognosis prediction were developed.

Benefits of technology

Accurate prediction of mesothelioma prognosis is achieved, with high accuracy, sensitivity and universality. The AUC predicted in 1 year, 3 years and 5 years are all greater than 0.7. For the first time, ferrodysfunction gene is used as a molecular marker for mesothelioma Prognosis prediction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118086505B_ABST
    Figure CN118086505B_ABST
Patent Text Reader

Abstract

The present invention provides a method for predicting the prognosis of mesothelioma, a molecular marker, a kit and an application thereof, the method comprising the following steps: (1) extracting RNA from a sample and converting the RNA into cDNA using a reverse transcriptase; (2) using primers and SYBR Green amplifies and quantifies the cDNA obtained in step (1); (3) detects the expression levels of CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4 through step (2) to obtain the corresponding expression signals; (4) the mesothelioma prognosis prediction risk score is recorded as the mesothelioma prognosis prediction result as Y, and the relationship between Y and the expression signal in step (3) is: Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(‑0.0554)×SLC7A11+(‑0.0214)×DPP4. The mesothelioma prognosis prediction method, molecular marker and kit of the present invention have good universality, high accuracy and sensitivity, and the AUC of the 1-year, 3-year and 5-year predicted prognosis is greater than 0.7.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of tumor marker genes, and in particular to a mesothelioma prognosis prediction method, a molecular marker, a kit and applications thereof. Background Art

[0002] Mesothelioma is a deadly cancer that originates from the serosa of multiple chambers of the body, including the pleura, pericardium, testis and its accessory structures. The specific pathological mechanism of mesothelioma development is still unclear. Its prognosis is extremely poor, with an average survival of about one year from the first onset of symptoms. Therefore, there is a need for methods and markers for the prediction of mesothelioma. Summary of the invention

[0003] The purpose of the present invention is to overcome the deficiencies of the prior art and provide a mesothelioma prognosis prediction method, a molecular marker and a kit and their application.

[0004] To achieve the above object, the technical solution adopted by the present invention is: a method for predicting the prognosis of mesothelioma, the method comprising the following steps:

[0005] (1) Extract RNA from the sample and convert it into cDNA using reverse transcriptase;

[0006] (2) amplifying and quantifying the cDNA obtained in step (1) using primers and SYBR Green;

[0007] (3) detecting the expression levels of CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4 through step (2) to obtain corresponding expression signals;

[0008] (4) Mesothelioma prognosis prediction risk score is recorded as the mesothelioma prognosis prediction result as Y. The relationship between Y and the expression signal in step (3) is: Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(-0.0554)×SLC7A11+(-0.0214)×DPP4.

[0009] Ferroptosis is a regulated cell death mechanism that depends on iron ions, which is characterized by the disturbance of cellular iron homeostasis and the abnormal accumulation of lipid peroxides. In recent years, a large number of important studies have revealed the key role of ferroptosis in various pathological processes, especially its contribution to the proliferation and metastasis of malignant tumor cells. These results suggest that ferroptosis plays an important role in the occurrence and development of malignant tumors and can be used as an independent factor to predict patient prognosis. However, there is no study on the relationship between mesothelioma and ferroptosis genes, and there are many types of ferroptosis genes. Whether they can be used as markers for mesothelioma and which ferroptosis genes are related to mesothelioma need further study. In order to obtain the above-mentioned mesothelioma prognosis prediction method, the study classified 24 ferroptosis regulators as key regulatory genes in the field of ferroptosis, given their crucial role in monitoring the complexity of the ferroptosis process. In order to identify ferroptosis regulators with significant prognostic information, we performed univariate Cox regression analysis and found nine genes with prognostic importance. The nine genes are related to each other. The nine genes need to be used as a combination of molecular markers for mesothelioma prognosis prediction in order to more accurately predict the prognosis of mesothelioma. The lack of any gene marker will lead to inaccurate prediction. The nine predictive ferroptosis regulators were used to construct a prognostic gene model using multivariate Cox iterative regression, Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(-0.0554)×SLC7A11+(-0.0214)×DPP4. For the first time, the use of ferroptosis genes as molecular markers to predict the prognosis of mesothelioma has been realized, and the marker combination with the best prediction accuracy has been screened out. It has good universality, high accuracy and sensitivity, and its 1-year, 3-year, and 5-year predicted prognosis AUCs are all greater than 0.7.

[0010] Preferably, the primers are SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 10, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No:15, SEQ ID No:16, SEQ ID No:17, SEQ ID No:18;

[0011] The sequences of the primers are shown in Table 1 below:

[0012] Primer Sequence(3’-5’) SEQ ID No: CARS1-F GGTGACGTGGTATTGCTGTG 1 CARS1-R CTCTTCTCCCGATACTGCTCG 2 CDKN1A-F TGTCCGTCAGAACCCATGC 3 CDKN1A-R AAAGTCGAAGTTCCATCGCTC 4 TFRC-F ACCATTGTCATATACCCGGTTCA 5 TFRC-R CAATAGCCCAAGTAGCCAATCAT 6 FANCD2-F ACATACCTCGACTCATTGTCAGT 7 FANCD2-R TCGGAGGCTTGAAAGGACATC 8 FDFT1-F CCACCCCGAAGAGTTCTACAA 9 FDFT1-R TGCGACTGGTCTGATTGAGATA 10 HSPB1-F ACGGTCAAGACCAAGGATGG 11 HSPB1-R AGCGTGTATTTCCGCGTGA 12 SLC1A5-F TCATGTGGTACGCCCCTGT 13 SLC1A5-R GCGGGCAAAGAGTAAACCCA 14 SLC7A11-F TCTCCAAAGGAGGTTACCTGC 15 SLC7A11-R AGACTCCCCTCAGTAAAGTGAC 16 DPP4-F TACAAAAGTGACATGCCTCAGTT 17 DPP4-R TGTGTAGAGTATAGAGGGGCAGA 18

[0013] Preferably, the prognosis prediction method is used to predict the prognosis for 1 to 5 years.

[0014] The AUCs of the above-mentioned prognostic prediction methods for 1-year, 3-year, and 5-year predictions are all greater than 0.7, showing good universality, high accuracy, and high sensitivity.

[0015] The present invention also provides a molecular marker for predicting the prognosis of mesothelioma, wherein the biomarker is a ferroptosis-related gene, and the gene includes: CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4.

[0016] Ferroptosis plays an important role in the occurrence and development of malignant tumors and can be used as an independent factor to predict patient prognosis. However, there is no research on the relationship between mesothelioma and ferroptosis genes, and there are many types of ferroptosis genes. Whether they can be used as markers for mesothelioma and which ferroptosis genes are related to mesothelioma requires further study. The study classified 24 ferroptosis regulators as key regulatory genes in the field of ferroptosis, given their crucial role in monitoring the complexity of the ferroptosis process. In order to identify ferroptosis regulators with significant prognostic information, we performed univariate Cox regression analysis and found nine genes with prognostic importance. The nine genes are related to each other. The nine genes need to be used as a combination of molecular markers for mesothelioma prognosis prediction in order to more accurately predict the prognosis of mesothelioma. The lack of any gene marker will lead to inaccurate prediction. The nine predictive ferroptosis regulators were used to construct a prognostic gene model using multivariate Cox iterative regression, Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(-0.0554)×SLC7A11+(-0.0214)×DPP4. For the first time, the use of ferroptosis genes as molecular markers to predict the prognosis of mesothelioma has been realized, and the marker combination with the best prediction accuracy has been screened out. It has good universality, high accuracy and sensitivity, and its 1-year, 3-year, and 5-year predicted prognosis AUCs are all greater than 0.7.

[0017] Preferably, the mesothelioma prognosis prediction risk score is recorded as Y as the mesothelioma prognosis prediction result, and the relationship between Y and the expression signal of the molecular marker is: Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(-0.0554)×SLC7A11+(-0.0214)×DPP4.

[0018] The present invention also provides a kit, which includes molecular markers and primers for predicting the prognosis of mesothelioma; the biomarkers are ferroptosis-related genes, and the genes include: CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4; the primers are: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 10, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18; the sequences of the primers are shown in Table 1.

[0019] The above-mentioned kit is the first mesothelioma prognosis model and diagnostic kit constructed based on ferroptosis-related genes, which can more accurately predict the prognosis of mesothelioma patients.

[0020] Preferably, the kit further comprises SYBR Green and reverse transcriptase.

[0021] Preferably, the kit further comprises an instruction manual, wherein the instruction manual records the method as claimed in claims 1 to 3.

[0022] The beneficial effects of the present invention are as follows: the present invention provides a mesothelioma prognosis prediction method, molecular markers and kit and applications thereof. The mesothelioma prognosis prediction method, molecular markers and kit of the present invention have good universality, high accuracy and sensitivity, and the AUCs of the 1-year, 3-year and 5-year predicted prognosis are all greater than 0.7. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1The prognostic value of the molecular markers in the mesothelioma prognosis prediction method of the present invention in mesothelioma. The overall survival curve of the high / low expression group of CARS1 A, CDKN1A B, TFRC C, FANCD2 D, FDFT1 E, HSPB1 F, SLC1A5 G, SLC7A11 H and DPP4 I in mesothelioma patients.

[0024] Figure 2 . Construct a prognostic gene model for the mesothelioma prognosis prediction method of the present invention.

[0025] A. Distribution of risk score, survival status, and expression of nine prognostic ferroptosis regulators in mesothelioma. B, C. Overall survival curves of mesothelioma patients in high / low risk groups and ROC curves measuring the predictive value.

[0026] Figure 3 The present invention is to construct a prediction nomogram for the mesothelioma prognosis prediction method. A, B Hazard ratios and P values ​​of clinical parameters and ferroptosis gene model risk scores in mesothelioma are considered in univariate and multivariate Cox regression analysis. DETAILED DESCRIPTION

[0027] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.

[0028] Example 1

[0029] As a mesothelioma prognosis prediction method according to an embodiment of the present invention, the method comprises the following steps:

[0030] (1) Extract RNA from the sample and convert it into cDNA using reverse transcriptase;

[0031] (2) amplifying and quantifying the cDNA obtained in step (1) using primers and SYBR Green;

[0032] (3) detecting the expression levels of CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4 through step (2) to obtain corresponding expression signals;

[0033] (4) Mesothelioma prognosis prediction risk score is recorded as the mesothelioma prognosis prediction result as Y. The relationship between Y and the expression signal in step (3) is: Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(-0.0554)×SLC7A11+(-0.0214)×DPP4.

[0034] The primers are: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 10, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18; the sequences of the primers are shown in Table 1;

[0035] The prognosis prediction method is used to predict the prognosis within 1 to 5 years.

[0036] Example 2

[0037] As a molecular marker for mesothelioma prognosis prediction in an embodiment of the present invention, the biomarker is a ferroptosis-related gene, and the gene includes: CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4;

[0038] The mesothelioma prognosis prediction risk score was recorded as Y as the mesothelioma prognosis prediction result. The relationship between Y and the expression signal of the molecular marker was: Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(-0.0554)×SLC7A11+(-0.0214)×DPP4.

[0039] Example 3

[0040] As a kit of an embodiment of the present invention, the kit includes molecular markers and primers for mesothelioma prognosis prediction;

[0041] The biomarkers are ferroptosis-related genes, including CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4; the primers are: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 10, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18; the sequences of the primers are shown in Table 1;

[0042] The kit also includes SYBR Green and reverse transcriptase;

[0043] The kit also includes instructions, which record the method described in Example 1.

[0044] Experimental methods

[0045] 1. Data collection and processing: We obtained the RNA-seq data set and related clinical information of 87 mesothelioma patients from the TCGA database as of April 1, 2021, as shown in Table 2. We used R (version 4.0.5) and the RBioconductor package to analyze our data. Before further analysis, the expression data of the RNA-seq data set of 87 mesothelioma patients obtained from the TCGA database were first standardized to transcripts per kilobase pair per million (TPM) values ​​to ensure the consistency and comparability of the data. The following are the specific steps for standardization to TPM values: Step 1: Calculate the raw read counts (Raw Read Counts), obtain the raw sequence read counts from the TCGA database, and these read counts represent the raw expression level of each gene. Step 2: Convert to read counts per kilobase pair (RPK): For each gene, you first need to calculate its read count per kilobase pair (RPK). The formula is as follows:

[0046]

[0047] Here, gene length refers to the length of the gene coding region, measured in kilobase pairs (kb).

[0048] Step 3: Calculate the transcript per kilobase pair per million (TPM). To ensure that the data is comparable between samples, the RPK value needs to be converted to the TPM value. The TPM calculation takes into account the sum of the RPK values ​​of all genes in order to standardize each sample. The formula is as follows:

[0049]

[0050] The denominator is the sum of the RPK values ​​of all genes, ensuring that the TPM value of each sample sums to one million across all genes, which allows for comparison between different samples because it takes into account the effects of sequencing depth and gene length.

[0051] Table 2 RNA-seq datasets and related clinical information of mesothelioma patients

[0052]

[0053] 2. Construction of prediction model: A set of 24 ferroptosis regulators, including LPCAT3, HSPA5, CARS1, CDKN1A, CS, GLS2, ALOX15, SAT1, ACSL4, EMC2, RPL8, FANCD2, NFE2L2, DPP4, TFRC, ATP5MC3, GPX4, FDFT1, MT1G, NCOA4, SLC7A11, HSPB1, CISD1, and SLC1A5 genes, were used to evaluate the predictive significance of ferroptosis regulators using Cox regression models. Kaplan-Meier survival analysis plots were used to derive p-values, hazard ratios (HRs), and 95% confidence intervals (CIs), and log-rank tests and Cox proportional hazard analysis were used for univariate analysis. Of note, ferroptosis regulators that showed significant prognostic significance were marked as subjects for follow-up review. After this, a prediction model was created based on the selected ferroptosis regulators using multivariate cox iterative regression. Subsequently, patients diagnosed with TCGA mesothelioma were divided into two subgroups: low-risk and high-risk, based on the risk score calculated at the median. The OS (overall survival) duration of these two subgroups was compared using Kaplan-Meier survival estimates. To evaluate the predictive accuracy of the genes and risk scores, a temporal ROC performance analysis was performed. Taking into account patient characteristics, a prediction chart was made to predict the probability of survival at 1, 3, and 5 years. 3. Validation of the ferroptosis risk score model: This study analyzed frozen tissues and data containing identifiable personal information provided by patients who underwent surgical treatment or biopsy at Sun Yat-sen Memorial Hospital of Sun Yat-sen University between 2015 and 2022. The focus of the study was patients with a confirmed diagnosis of mesothelioma by detailed pathological examination. The key criteria for participant inclusion included: a definite diagnosis of mesothelioma, no prior anticancer treatment before biopsy, and comprehensive clinical pathology records and extensive follow-up data. Samples and data were obtained from the Institute of Pathology and Department of Oncology of the hospital. The study was conducted in accordance with relevant laws and institutional guidelines, and ethical approval was obtained from the Ethics Committee of Sun Yat-sen Memorial Hospital of Sun Yat-sen University, and informed consent was waived with the approval of the Ethics Committee. RT-PCR was used to detect the expression levels of CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11, and DPP4, and the risk score was calculated according to the above model. Then, the clinicopathological characteristics and risk scores were subjected to COX univariate and multivariate analysis, and COX regression forest plots were drawn using “survival” (version 3.4.0), “survminer” (version 0.4.9), and “forestplot” (version 2.0.1) of R software (version 4.2.2).

[0054] The 24 ferroptosis regulatory factors are shown in Table 3.

[0055] Table 3 24 ferroptosis regulatory factors

[0056] ACSL4 acyl-CoA synthetase long-chain family member 4 ALOX15 arachidonate 15-lipoxygenase ATP5G3 ATP synthase, H+ transporting, mitochondrial Fo complex subunit C3 CARS1 cysteinyl tRNA synthetase 1 CDKN1A cyclin-dependent kinase inhibitor 1 CISD1 CDGSH iron sulfur domain 1 CS citrate synthase DPP4 dipeptidyl-dippeptidase-4 FANCD2 Fanconi anemia complementation group D2 FDFT1 farnesyl-diphosphate farnesyltransferase 1 GLS2 glutaminase 2 GPX4 glutathione peroxidase 4 HSPA5 heat shock protein family A member 5 HSPB1 heat shock protein beta 1 LPCAT3 lysophosphatidylcholine acyltransferase 3 MT1G metallothionein-1G NCOA4 nuclear receptor coactivator 4 NFE2L2 nuclear factor, erythroid 2 like 2 RPL8 ribosomal protein L8 SAT1 spermidine / spermine N1-acetyltransferase 1 SLC1A5 solute carrier family 1 Member 5 SLC7A11 solute carrier family 7 member 11 TFRC transferrin receptor TTC35 / EMC2 ER membrane protein complex subunit 2

[0057] 4. The specific steps of PCR can be summarized as follows: The real-time quantitative reverse transcription polymerase chain reaction (RT-PCR) experiment mainly includes extracting RNA from mesothelioma tissue samples, evaluating its purity and concentration by UV spectroscopy, converting RNA into cDNA using reverse transcriptase, and then amplifying and quantifying cDNA in a real-time PCR instrument using primers for CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4 and SYBR Green. The specific primer sequences are shown in Table 1.

[0058] Experimental Results

[0059] 1. A set of 24 ferroptosis regulatory factors, including LPCAT3, HSPA5, CARS1, CDKN1A, CS, GLS2, ALOX15, SAT1, ACSL4, EMC2, RPL8, FANCD2, NFE2L2, DPP4, TFRC, ATP5MC3, GPX4, FDFT1, MT1G, NCOA4, SLC7A11, HSPB1, CISD1, and SLC1A5, were used to evaluate the predictive significance of ferroptosis regulatory factors using the Cox regression model. Kaplan-Meier survival analysis plots were used to obtain p-values, hazard ratios (HRs), and 95% confidence intervals (CIs), and log-rank tests and Cox proportional hazard analysis were used for univariate analysis. After the above analysis, nine of the twenty-four ferroptosis genes were found to be prognostic, and their corresponding Kaplan-Meier survival curves were displayed. The results showed that CARS1 ( Figure 1 A, p=0), CDKN1A ( Figure 1 B, p=0.006), TFRC ( Figure 1 C, p=0.045), FANCD2 ( Figure 1 D, p=0), FDFT1( Figure 1 E, p=0), HSPB1 ( Figure 1 F, p=0.007), SLC1A5 ( Figure 1 G, p=0.001), SLC7A11 ( Figure 1 H, p=0.001) and decreased expression levels of DPP4 ( Figure 1I, p = 0.048) showed an unfavorable survival trend in mesothelioma patients. These nine predictive ferroptosis regulators were used to construct a prognostic gene model using multivariate cox iterative regression.

[0060] 2. Using the risk score, patients with malignant mesothelioma were divided into two cohorts, and their risk score distribution, survival outcomes, and gene expression patterns of these nine regulators were compared in Figure 2 C. As the risk score increases, the patient's risk of death increases accordingly, while their overall survival time decreases, as shown in Figure 2 C. According to Kaplan-Meier analysis, the overall survival rate of mesothelioma patients with high risk scores was significantly reduced compared with the low-risk control group (median overall survival time = 1 year vs. 2.1 years, p = 6.29 × 10 -6 , Figure 2 B). In addition, Figure 2 As shown in C, in the ROC curves at the 1-year, 3-year, and 5-year time points, the AUC indicators were 0.804, 0.865, and 0.873, respectively.

[0061] 3. Validation of the risk score model: The present invention collected frozen tissue specimens of 36 patients with mesothelioma from the Sun Yat-sen Memorial Hospital of Sun Yat-sen University, detected the expression levels of 9 ferroptosis-related genes in the model by RT-PCR, and calculated the risk score of the ferroptosis gene prognostic model of the patients based on the above model. We constructed a prognostic nomogram to estimate the survival probability of patients based on the clinical pathological characteristics and risk scores of the patients. Both univariate and multivariate analyses suggested that the risk score and pM stage were independent prognostic indicators for mesothelioma patients ( Figure 3 A, B).

[0062] Experimental results show that the mesothelioma prognosis prediction method, molecular markers and kit of the present invention have good universality, high accuracy and sensitivity, and the AUC of the 1-year, 3-year and 5-year predicted prognosis is greater than 0.7.

[0063] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A molecular marker for predicting the prognosis of mesothelioma, It is characterized in that The molecular markers are ferroptosis-related genes, including CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4; The molecular markers are obtained by amplification of the following primers: SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18; The sequences of the primers are shown in the following table: 。 2. The molecular marker for predicting the prognosis of mesothelioma according to claim 1, It is characterized in that The mesothelioma prognosis prediction risk score was recorded as Y as the mesothelioma prognosis prediction result. The relationship between Y and the expression signal of the molecular marker was: Y=0.6976×CARS1+0.3167×CDKN1A+0.0887×TFRC+0.8286×FANCD2+0.1581×FDFT1+0.4534×HSPB1+0.2378×SLC1A5+(-0.0554)×SLC7A11+(-0.0214)×DPP4.

3. A kit, It is characterized in that The kit includes molecular markers and primers for mesothelioma prognosis prediction; The molecular markers are ferroptosis-related genes, including CARS1, CDKN1A, TFRC, FANCD2, FDFT1, HSPB1, SLC1A5, SLC7A11 and DPP4; the primers are SEQ ID No: 1, SEQ ID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7, SEQ ID No: 8, SEQ ID No: 9, SEQ ID No: 10, SEQ ID No: 11, SEQ ID No: 12, SEQ ID No: 13, SEQ ID No: 14, SEQ ID No: 15, SEQ ID No: 16, SEQ ID No: 17, SEQ ID No: 18; The sequences of the primers are shown in the following table: 。 4. The kit according to claim 3, It is characterized in that The kit also includes SYBR Green and reverse transcriptase.

5. The kit according to claim 3, It is characterized in that The kit also includes instructions for use.